A trend toward significance was observed for four-year PFS (71%, 58%, and 42% for AA, AG, and GG genotypes, respectively; p = 0.06), while four-year OS differed significantly across the three subgroups (78%, 61%, and 45%, respectively; p = 0.04).
Detection of FRE colonization on pre-transplant testing predicted for subsequent re-hospitalization ( p = 0.002); the detection of FRE colonization, including the post-transplant samples, was of borderline significance ( p = 0.06).
There was no significant variable to predict major revision, although the administration of perioperative chemotherapy was a marginally significant variable ( p = 0.06).
Patients with delayed surgery (C3) showed a non-significant trend toward increased risk (HR 5.05; 95% CI 0.53–48.6; p = 0.161), and those who did not undergo indicated surgery (C4) demonstrated borderline significance (HR 7.27; 95% CI 0.92–57.5; p = 0.060).
CRT significantly reduced local progression rates (32% versus 46%, p = 0.030) and showed a trend towards better median PFS (9.9 versus 8.4 months, p = 0.060) and longer median time without retreatment (6.1 versus 3.7 months, p = 0.020).
Intriguingly, Binet stage C patients tended to have a higher level of RelB activity compared to stage A patients ( Figure 6 F), but this did not quite reach significance ( p = 0.06), likely due to three Binet stage A cases that had high RelB activity (including one with ATM loss).
We observed a statistically significant genotype-by-sex interaction for MDM4 rs4245739 ( p = 0.01) and a borderline significant interaction for rs1563828 ( p = 0.06).
Stage IV disease demonstrated a borderline significant association with worse disease-free survival, with a HR of 2.81 (95% CI 0.96–8.27, p = 0.06) compared to stages I-III.
Although only approaching significance, DGE and PPH presented a higher frequency in the PPAP population than in the no-PPAP group ( p = 0.06 and 0.08, respectively).
ATRX gene conservation showed a favorable trend in terms of OS despite a significant result was not reached ( p = 0.06; median OS of 11 months vs. 29 months, respectively for ATRX positive vs. negative; HR 2.69, 95% CI 0.92–7.83).
After 4 weeks, X-rays and μCT analyses showed a trend of reduction in osteolytic lesion incidence (chi-square test; p = 0.06) ( Figure 2 b and Supplementary Figure S2a ) along with a reduced osteolytic area ( Figure 2 c,d) in the tibias of N-Cadherin High compared to N-Cadherin Low cell-injected mice.
There was an observed trend towards longer operative time for the MIS-ILND approach (mean difference 28 min; 95% CI −2 to 58 min, p = 0.06), particularly with the robotic-assisted technique.
In univariable analyses, germline variation in GZMB and PDCD1 showed a trend towards associations with OS according to the dominant model (HR 1.811, 95%CI 0.945–3.364, p = 0.060 and HR 2.027, 95%CI 0.998–4.118, p = 0.051, respectively).
Although not statistically significant, patients with recurrent disease showed a trend toward longer OS and PFS than those with unresectable disease (OS, p = 0.06; PFS, p = 0.05) ( Figure 2 ).
Furthermore, genetic ancestry, specifically African American ancestry, was also significantly associated with CIPN change from baseline (CE = −7.63, SE = 2.43, and p < 0.002) with an overall significance of p = 0.007, while sex was only borderline significant (CE = 3.29, SE = 1.77, and p = 0.06), Table 2 .